TY  - JOUR
A1  - Sisignano, Marco
A1  - Gribbon, Philip
A1  - Geisslinger, Gerd
T1  - Drug repurposing to target neuroinflammation and sensory neuron-dependent pain
T2  - Drugs
N2  - Around 20% of the American population have chronic pain and estimates in other Western countries report similar numbers. This represents a major challenge for global health care systems. Additional problems for the treatment of chronic and persistent pain are the comparably low efficacy of existing therapies, the failure to translate effects observed in preclinical pain models to human patients and related setbacks in clinical trials from previous attempts to develop novel analgesics. Drug repurposing offers an alternative approach to identify novel analgesics as it can bypass various steps of classical drug development. In recent years, several approved drugs were attributed analgesic properties. Here, we review available data and discuss recent findings suggesting that the approved drugs minocycline, fingolimod, pioglitazone, nilotinib, telmisartan, and others, which were originally developed for the treatment of different pathologies, can have analgesic, antihyperalgesic, or neuroprotective effects in preclinical and clinical models of inflammatory or neuropathic pain. For our analysis, we subdivide the drugs into substances that can target neuroinflammation or substances that can act on peripheral sensory neurons, and highlight the proposed mechanisms. Finally, we discuss the merits and challenges of drug repurposing for the development of novel analgesics.
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/69577
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-695771
SN  - 1179-1950
N1  - Open Access funding enabled and organized by Projekt DEAL. This work was supported by Grants SFB1039 A09 and Z01 of the Deutsche Forschungsgemeinschaft (German Research Foundation) and from the Fraunhofer Foundation Project: Neuropathic Pain as well as the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD)
VL  - 82
IS  - 4
SP  - 357
EP  - 373
PB  - Springer
CY  - Berlin [u.a.]
ER  -